The global immunoprecipitation market is expected to grow from USD 560 million in 2018 to USD 750 million by 2024, at a CAGR of 5.0% during the forecast period. The growth of this market is majorly driven by the increasing number of research activities in the life sciences industry and the growing need to identify antigens associated with autoimmune diseases (through antigen-antibody interaction to understand disease mechanisms and develop relevant drugs targeting these diseases).
The major immunoprecipitation vendors include Thermo Fisher Scientific (US), Abcam (UK), Bio-Rad Laboratories (US), Merck KGaA (Germany), GenScript. (US), and BioLegend (US), Cell Signaling Technology (US), Rockland Immunochemicals (US), Takara Bio (Japan), and Geno Technology (US). These players have adopted various growth strategies such as acquisition, product launches, agreements, partnerships, collaboration, and expansion to expand their presence in the immunoprecipitation market.
Thermo Fisher Scientific is the leading player in the global immunoprecipitation market. It offers kits, research antibodies, and reagents in the immunoprecipitation market. Owing to its strong sales and distribution network, the company has a significant global footprint. The company leverages the advantage of its well-established brands—Thermo Scientific, Fisher Scientific, Unity Lab Services, and Life Technologies. Under these four brands, the company has a very strong product portfolio for antibodies and other reagents used in immunoprecipitation assays. The company aims to strengthen its presence in selected geographies by undertaking various organic and inorganic growth strategies. Thermo Fisher expanded its presence in the US and South Korea in 2016 by opening new GMP facilities. Furthermore, with the acquisition of Affymetrix in 2016, the company expanded its research antibodies portfolio.
To know about the assumptions considered for the study download the pdf brochure
Abcam is one of the largest players in the immunoprecipitation market. The company leads the primary research antibodies market and is also engaged in the supply of a wide range of secondary antibodies and kits for immunoprecipitation assays. Abcam is one of the leading providers of high-quality antibodies at the global scale, and high consumer awareness makes it a well-known brand in this market. It invests in the discovery of new antibody manufacturing technologies to speed up the pace of scientific research to increase its product offerings. The company has a strong presence in the European and Asia Pacific markets, with manufacturing facilities in the UK, Japan, and China. The company also has a significant market presence in the US. It continues to grow in excellence through product launches and agreements, thereby maintaining its position in the market. In line with this strategy, the company launched a wide number of antibodies along with antibody kits from 2016 to 2018.
Merck is a key player in the immunoprecipitation market. The company has a strong product and custom services portfolio for research antibodies and offers innovative solutions for the life science industry. With a strong brand name and wide geographic coverage in more than 60 countries, Merck has a well-established presence in the immunoprecipitation market. As a part of its global growth strategy, the company is investing in the fast-growing life science industry by entering into synergies with companies like Sigma-Aldrich. In the immunoprecipitation market, the company focuses on expanding its reach with the aim of interacting with researchers and scientists to harmonize various research study processes. With regard to this, the company opened an M Lab Collaboration Center in Brazil in October 2018. This center will provide Merck’s life science customers with a shared, exploratory environment where it can closely collaborate with Merck scientists and engineers to develop processes for manufacturing drugs. With regard to providing innovative products, Merck invests a significant amount of its sales revenue in R&D. In 2017, it invested around 14% of its sales revenue in R&D activities. This allows the company to extend its technological capabilities and provide superior-quality products, thereby helping the company to achieve long-term growth.
Immunoprecipitation Market by Product (Kit, Reagent (Antibodies, Magnetic Buffer)), Type (Individual IP, Coimmunoprecipitation, CHIP), End User (Academics, Research Institutes, Pharmaceutical and Biotechnology Companies) - Global Forecast to 2024
Mr. Shelly Singh
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE